Camtek Ltd.
CAMTCamtek Ltd.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +58.8% in a year while annual EPS moved −57.0% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (1 weeks in). Underneath, the last four quarters read mixed — profit +0.0% year on year, and 136% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Camtek Ltd. trades at $152, in a confirmed uptrend and 1 weeks into that stage. That is +2.4% against its own 200-day average. It sits at 57% of a 52-week range of $79 to $206. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (7 weeks and counting).
Today the stock is in a confirmed uptrend — week 1 of stage 2. At $152 it trades +2.4% versus its 200-day average and sits at 57% of its 52-week range ($79–$206).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +6,609% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (7 weeks and counting; last ahead the week of 2026-06-18) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Camtek Ltd. trades at 152.7× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 152.7× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −57.0% against a +58.8% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +47.8%/yr price move, ~−18.7%/yr came from earnings growth and ~+66.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Camtek Ltd. reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −58.3% latest against +50.0% at its 12-quarter best), ROCE slipping at 12.1%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +16.3% | +16.0% | — | — |
| Profit | −58.3% | −14.5% | — | — |
| EPS | −57.0% | −14.8% | — | — |
| Stock price | +58.8% | +47.8% | +32.1% | +50.2% |
4-Factor Sector Score
39.3/100 — rank 22 of 29 in Semiconductor Equipment & Materials · 81% evidence confidence
Camtek Ltd. scores 39.3 out of 100 against the 29 companies it is compared with in Semiconductor Equipment & Materials, ranking 22. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11 + 13.5 + 11.8 + 3 = 39.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Camtek Ltd. reported $0.1 B of revenue in the Mar 26 quarter, +0.0% year on year. Over 4 years it has compounded at 16.7% a year. The last full year, FY25, came in at $0.5 B. The last four reported quarters add to $0.5 B.
FY25 revenue came in at $0.5 B (+16.3% on the year), capping 4 years at 16.7% compound. The latest quarter (Mar 26) printed $0.1 B, +0.0% year on year.
Pace check: the last four quarters averaged +11.6% growth against the decade's 16.7% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +11.1% over the last 4 quarters against +21.3%/yr over the last 8 — rolling over; TTM profit −58.3% vs −20.9%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Camtek Ltd.'s operating margin is 25.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 21.9% to 26.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 25.0%, +0.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 21.9%–26.0%, and FY25's 26.0% is the top of that band — a record year.
Why the margin moved: operating margin went +0.0 pp year on year while gross margin went +0.0 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Camtek Ltd. earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.1 B. The 4-year compound rate is −4.5%. That is 25.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.0 B, +0.0% year on year. On the full year, FY25 printed $0.1 B (−58.3%), and the 4-year compound rate is −4.5%.
🚨 Why profit moved: revenue contributed +0.0% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −58.3% vs revenue +11.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 136% of Camtek Ltd.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.1 B of operating cash against $0.1 B of profit. After $0.0 B of capital spending, $0.1 B was left as free cash.
FY25: operating cash of $0.1 B against reported profit of $0.1 B, leaving free cash of $0.1 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 136% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Camtek Ltd. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Camtek Ltd. earns a ROE of 8% in FY25. Return on invested capital clears the cost of that capital by +12.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.0% net margin on 0.40× asset turns.
FY25 ROE is 8%.
Why the return is what it is — the wiring (FY25): 10.0% net margin × 0.40× asset turns × 2.03× balance-sheet leverage ≈ 8.1% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 25.0% − 12.2% = a +12.8 pp spread. The 12.2% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Camtek Ltd. has 1 quarter of declared dividends on file — too few for a trailing-twelve-month figure. The most recent declaration was $1.33 for Mar 24.
Camtek Ltd. has declared a dividend in 1 of the last 12 reported quarters, most recently $1.33 for Mar 24. That is fewer than four quarters, so no trailing-twelve-month total is shown rather than one built from a partial year.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Camtek Ltd. carries total debt of $0.5 B against shareholder equity of $0.7 B as of Mar 26, a debt-to-equity of 0.72. On the annual view that ratio went from 0.63 in FY21 to 0.84 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $0.5 B against shareholder equity of $0.7 B — a debt-to-equity of 0.72. On the annual view, debt-to-equity went from 0.63 (FY21) to 0.84 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
No ownership or positioning reading is held for Camtek Ltd., so this section names the gap rather than filling it. At typical trading volumes those positions would take about 4.7 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
We hold no ownership or positioning reading for this stock, so this section says that plainly.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Camtek Ltd.: the Z-score reads 6.60. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 6.60 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 6.60.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Teradyne, Inc.TER | 69.6/100Thin evidence · provisional58% evidence | TURNING | 24.3/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence | 18.4/25 ROCE 12.7% · OPM 36.9% 76% evidence | 10.1/20 P/E 59.9× · PEG — 15% evidence | 16.8/20 RS sector 5.5% · RS bench 40% · 1Y 275.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 18.4 + 10.1 + 16.8 = 69.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Applied Materials, Inc.AMAT | 68.2/100Favorable setup85% evidence | LEADER | 22.1/35 Revenue 3.3% · PAT 25.9% · OPM change 1.4 pp 95% evidence | 16.4/25 ROCE 8.9% · OPM 31.9% 76% evidence | 11.1/20 P/E 39.2× · PEG 1.32 65% evidence | 18.6/20 RS sector 7.8% · RS bench 44.6% · 1Y 195.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 16.4 + 11.1 + 18.6 = 68.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Lam Research CorporationLRCX | 63.8/100Thin evidence · provisional58% evidence | FADING | 21.9/35 Revenue — · PAT — · OPM change 1.9 pp 45% evidence | 19.4/25 ROCE 15.5% · OPM 35% 76% evidence | 9.6/20 P/E 65.8× · PEG — 15% evidence | 12.9/20 RS sector -2.8% · RS bench 30.9% · 1Y 212.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 19.4 + 9.6 + 12.9 = 63.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4ACM Research, Inc.ACMR | 60.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 17.6/35 Revenue 19.7% · PAT -9% · OPM change 0.6 pp 83% evidence | 11.8/25 ROCE 2% · OPM 15.6% 76% evidence | 14.7/20 P/E 30× · PEG 0.75 65% evidence | 16.8/20 RS sector 2.7% · RS bench 38.8% · 1Y 244.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 11.8 + 14.7 + 16.8 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5ASML Holding N.V.ASML | 56.1/100Mixed-positive evidence85% evidence | FADING | 22.6/35 Revenue 9.8% · PAT 13.5% · OPM change 2.5 pp 95% evidence | 17.5/25 ROCE 11% · OPM 37.1% 76% evidence | 4.7/20 P/E 63.3× · PEG 4.28 65% evidence | 11.3/20 RS sector -15.3% · RS bench 18.8% · 1Y 137%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 17.5 + 4.7 + 11.3 = 56.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 6Kulicke and Soffa Industries, Inc.KLIC | 55.0/100Thin evidence · provisional58% evidence | FADING | 23.2/35 Revenue — · PAT — · OPM change 20 pp 45% evidence | 12.6/25 ROCE 4% · OPM 15.9% 76% evidence | 9.8/20 P/E 61.6× · PEG — 15% evidence | 9.4/20 RS sector -4.9% · RS bench 26.7% · 1Y 165%10 of 12 weeks ahead 100% evidence |
| Exact sum: 23.2 + 12.6 + 9.8 + 9.4 = 55 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7FormFactor, Inc.FORM | 54.6/100Thin evidence · provisional58% evidence | ASLEEP | 22.5/35 Revenue — · PAT — · OPM change 5.5 pp 45% evidence | 12.7/25 ROCE 5.2% · OPM 7.4% 76% evidence | 9.0/20 P/E 89.5× · PEG — 15% evidence | 10.4/20 RS sector 1.3% · RS bench 30.9% · 1Y 320.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 12.7 + 9 + 10.4 = 54.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8KLA CorporationKLAC | 54.3/100Thin evidence · provisional58% evidence | FADING | 16.4/35 Revenue — · PAT — · OPM change -1.3 pp 45% evidence | 18.2/25 ROCE 12.1% · OPM 41.2% 76% evidence | 9.2/20 P/E 82.4× · PEG — 15% evidence | 10.5/20 RS sector -15.5% · RS bench 16.9% · 1Y 113.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 18.2 + 9.2 + 10.5 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Cohu, Inc.COHU | 52.8/100Thin evidence · provisional58% evidence | FADING | 20.1/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence | 5.4/25 ROCE 0% · OPM -8.9% 76% evidence | 9.9/20 P/E 60× · PEG — 15% evidence | 17.4/20 RS sector 5.2% · RS bench 41.2% · 1Y 172.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 5.4 + 9.9 + 17.4 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10AXT, Inc.AXTI | 51.3/100Thin evidence · provisional58% evidence | ASLEEP | 22.1/35 Revenue — · PAT — · OPM change 47.2 pp 45% evidence | 7.0/25 ROCE 1.7% · OPM -5.9% 76% evidence | 8.5/20 P/E 3604× · PEG — 15% evidence | 13.7/20 RS sector 36.7% · RS bench 50.9% · 1Y 2950%5 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 7 + 8.5 + 13.7 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Aehr Test Systems, Inc.AEHR | 48.8/100Thin evidence · provisional58% evidence | TURNING | 15.7/35 Revenue — · PAT — · OPM change -34.9 pp 45% evidence | 5.0/25 ROCE -0.7% · OPM -41% 76% evidence | 11.5/20 P/E 12.4× · PEG — 15% evidence | 16.6/20 RS sector 65.3% · RS bench 106.2% · 1Y 503.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 5 + 11.5 + 16.6 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Amkor Technology, Inc.AMKR | 48.3/100Thin evidence · provisional58% evidence | FADING | 21.0/35 Revenue — · PAT — · OPM change 3.6 pp 45% evidence | 12.5/25 ROCE 3% · OPM 6% 76% evidence | 10.8/20 P/E 38.7× · PEG — 15% evidence | 4.0/20 RS sector -23% · RS bench 4.2% · 1Y 141.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 12.5 + 10.8 + 4 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Amtech Systems, Inc.ASYS | 48.2/100Thin evidence · provisional58% evidence | FADING | 20.5/35 Revenue -13.2% · PAT — · OPM change 211.5 pp 62% evidence | 9.3/25 ROCE 2.5% · OPM 8.8% 76% evidence | 9.3/20 P/E 68.7× · PEG — 15% evidence | 9.1/20 RS sector -11.2% · RS bench 19.9% · 1Y 259.6%8 of 12 weeks ahead 70% evidence |
| Exact sum: 20.5 + 9.3 + 9.3 + 9.1 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Ichor Holdings, Ltd.ICHR | 47.0/100Mixed-negative evidence64% evidence | FADING | 16.6/35 Revenue 7.6% · PAT — · OPM change 1.3 pp 62% evidence | 5.8/25 ROCE 0.2% · OPM 0.8% 76% evidence | 10.4/20 P/E 48.1× · PEG — 15% evidence | 14.2/20 RS sector 20.6% · RS bench 48.4% · 1Y 308.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 5.8 + 10.4 + 14.2 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 48.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Nova Ltd.NVMI | 46.4/100Mixed-negative evidence81% evidence | ASLEEP | 21.4/35 Revenue 21.4% · PAT 24.6% · OPM change 0.5 pp 83% evidence | 15.7/25 ROCE 5.6% · OPM 30.1% 76% evidence | 6.7/20 P/E 54.1× · PEG 2.56 65% evidence | 2.6/20 RS sector -34.6% · RS bench -7.4% · 1Y 53%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 15.7 + 6.7 + 2.6 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Photronics, Inc.PLAB | 45.4/100Mixed-negative evidence85% evidence | ASLEEP | 14.4/35 Revenue 0.5% · PAT 24.1% · OPM change -6.3 pp 95% evidence | 13.8/25 ROCE 2.6% · OPM 20.1% 76% evidence | 16.3/20 P/E 18.2× · PEG 0.43 65% evidence | 0.9/20 RS sector -36.1% · RS bench -9.2% · 1Y 61.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.4 + 13.8 + 16.3 + 0.9 = 45.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 17Ultra Clean Holdings, Inc.UCTT | 44.3/100Mixed-negative evidence64% evidence | FADING | 12.9/35 Revenue -3.2% · PAT -574.4% · OPM change -0.4 pp 62% evidence | 6.6/25 ROCE 0.7% · OPM 2.1% 76% evidence | 10.9/20 P/E 35.5× · PEG — 15% evidence | 13.9/20 RS sector 11.3% · RS bench 40.5% · 1Y 264.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 6.6 + 10.9 + 13.9 = 44.3 · Decision use: Price leads the evidence: RS versus the benchmark is 40.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Onto Innovation Inc.ONTO | 44.3/100Thin evidence · provisional56% evidence | FADING | 12.9/35 Revenue — · PAT — · OPM change -18.5 pp 39% evidence | 9.9/25 ROCE 0.7% · OPM 5.2% 76% evidence | 10.2/20 P/E 59.7× · PEG — 15% evidence | 11.3/20 RS sector -5.6% · RS bench 27.8% · 1Y 179.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 9.9 + 10.2 + 11.3 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Ambarella, Inc.AMBA | 44.2/100Mixed-negative evidence64% evidence | FADING | 22.3/35 Revenue 27.8% · PAT — · OPM change 10.8 pp 71% evidence | 3.5/25 ROCE -3.2% · OPM -19.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.4/20 RS sector -34.4% · RS bench 2.6% · 1Y 27.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 3.5 + 10 + 8.4 = 44.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20InTest CorporationINTT | 44.0/100Thin evidence · provisional58% evidence | ASLEEP | 19.5/35 Revenue -5.5% · PAT — · OPM change 13.6 pp 62% evidence | 8.2/25 ROCE 0.8% · OPM 2.8% 76% evidence | 8.6/20 P/E 341.3× · PEG — 15% evidence | 7.7/20 RS sector -16.9% · RS bench 13.1% · 1Y 103.8%4 of 12 weeks ahead 70% evidence |
| Exact sum: 19.5 + 8.2 + 8.6 + 7.7 = 44 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Entegris, Inc.ENTG | 42.6/100Mixed-negative evidence81% evidence | ASLEEP | 14.5/35 Revenue -0.3% · PAT -14.8% · OPM change 1.6 pp 83% evidence | 10.9/25 ROCE 1.8% · OPM 17.4% 76% evidence | 7.7/20 P/E 67× · PEG 1.93 65% evidence | 9.5/20 RS sector -19% · RS bench 14.7% · 1Y 97.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 10.9 + 7.7 + 9.5 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Camtek Ltd.this pageCAMT | 39.3/100Mixed-negative evidence81% evidence | ASLEEP | 11.0/35 Revenue 10.6% · PAT -61.7% · OPM change -5.2 pp 83% evidence | 13.5/25 ROCE 2.7% · OPM 22.4% 76% evidence | 11.8/20 P/E 174.3× · PEG 0.8 65% evidence | 3.0/20 RS sector -29.6% · RS bench -0.7% · 1Y 82.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 13.5 + 11.8 + 3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23IPG Photonics CorporationIPGP | 39.2/100Mixed-negative evidence74% evidence | ASLEEP | 14.8/35 Revenue 9.2% · PAT — · OPM change -3.7 pp 62% evidence | 6.8/25 ROCE -0.4% · OPM -2.9% 76% evidence | 13.0/20 P/E 166.1× · PEG 0.67 65% evidence | 4.6/20 RS sector -40.8% · RS bench -14% · 1Y 25%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 6.8 + 13 + 4.6 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Axcelis Technologies, Inc.ACLS | 38.6/100Mixed-negative evidence81% evidence | FADING | 7.8/35 Revenue -11.8% · PAT -44.1% · OPM change -11.1 pp 83% evidence | 9.8/25 ROCE 0.7% · OPM 4% 76% evidence | 12.5/20 P/E 29× · PEG 1.16 65% evidence | 8.5/20 RS sector -16% · RS bench 18.4% · 1Y 75.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 7.8 + 9.8 + 12.5 + 8.5 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Veeco Instruments Inc.VECO | 37.1/100Mixed-negative evidence81% evidence | FADING | 6.8/35 Revenue -7.8% · PAT -64.1% · OPM change -10.2 pp 83% evidence | 7.2/25 ROCE -0.2% · OPM -1.7% 76% evidence | 13.7/20 P/E 89.1× · PEG 0.65 65% evidence | 9.4/20 RS sector -8.9% · RS bench 25% · 1Y 128%9 of 12 weeks ahead 100% evidence |
| Exact sum: 6.8 + 7.2 + 13.7 + 9.4 = 37.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 26Daqo New Energy Corp.DQ | 28.0/100Thin evidence · provisional58% evidence | BASING | 9.2/35 Revenue -22.8% · PAT — · OPM change -472.4 pp 62% evidence | 4.4/25 ROCE -2.6% · OPM -564.4% 76% evidence | 11.4/20 P/E 12.5× · PEG — 15% evidence | 3.0/20 RS sector -68.5% · RS bench -48.5% · 1Y -36.8%0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.2 + 4.4 + 11.4 + 3 = 28 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Trio-Tech InternationalTRT | 53.0/100Thin evidence · provisional14% evidence | 17.5/35 Revenue — · PAT — · OPM change — 0% evidence | 12.5/25 ROCE — · OPM — 0% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.0/20 RS sector 0.1% · RS bench 43.9% · 1Y 259.6%8 of 8 weeks ahead to 2026-07-10 70% evidence | |
| Exact sum: 17.5 + 12.5 + 10 + 13 = 53 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Qnity Electronics, Inc.Q | 52.2/100Thin evidence · provisional38% evidence | ASLEEP | 16.7/35 Revenue — · PAT — · OPM change -0.4 pp 45% evidence | 15.0/25 ROCE 4.2% · OPM 20.6% 76% evidence | 10.5/20 P/E 45.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 12 weeks ahead 0% evidence |
| Exact sum: 16.7 + 15 + 10.5 + 10 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Atomera IncorporatedATOM | 43.8/100Thin evidence · provisional43% evidence | FADING | 21.8/35 Revenue — · PAT — · OPM change 79084.1 pp 39% evidence | 4.9/25 ROCE -19.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.1/20 RS sector -20% · RS bench 6.9% · 1Y 60.5%8 of 12 weeks ahead 70% evidence |
| Exact sum: 21.8 + 4.9 + 10 + 7.1 = 43.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Camtek Ltd.'s stock price today?
Camtek Ltd. trades at $152, +58.8% over the past year. The company is valued at $7.0 B. The stock sits at 57% of its 52-week range of $79–$206, +2.4% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 1 weeks in. — as of 5 August 2026.
What were Camtek Ltd.'s latest quarterly results?
Camtek Ltd. reported revenue of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 0.0% and profit rose 0.0% year on year. Earnings per share were $0.63. The operating margin was 25.0%, 0.0 pp higher than a year earlier. — as of 5 August 2026.
What is Camtek Ltd.'s revenue?
Camtek Ltd. reported revenue of $0.1 B in the Mar 26 quarter, +0.0% year on year. For the full FY25 fiscal year, revenue was $0.5 B (+16.3%). Over the last 4 years revenue compounded at 16.7% a year. — as of 5 August 2026.
What is Camtek Ltd.'s profit?
Camtek Ltd. earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.1 B. The operating margin ran 25.0% in the latest quarter. — as of 5 August 2026.
What is Camtek Ltd.'s market cap?
Camtek Ltd.'s market capitalisation is $7.0 B at a stock price of $152. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Camtek Ltd. pay a dividend?
Yes — Camtek Ltd. declared $1.33 per share for Mar 24 (1 quarter on file, too few for a trailing-twelve-month total). — as of 5 August 2026.
What is Camtek Ltd.'s dividend per share?
Camtek Ltd.'s most recently declared dividend is $1.33 per share for Mar 24. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
Is Camtek Ltd. growing?
The picture is mixed for Camtek Ltd.: latest-quarter revenue +0.0% year on year, profit +0.0%, and the margin +0.0 pp at 25.0%. The 4-year compound rates are 16.7% (revenue) and −4.5% (profit). The earnings engine currently reads: mixed — as of 5 August 2026.
How is Camtek Ltd. performing?
Camtek Ltd. is in a confirmed uptrend, 1 weeks in. Its latest quarter's revenue rose 0.0% and profit rose 0.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Camtek Ltd. in?
Deteriorating — profit and EPS growth are shrinking (profit growth −58.3% latest against +50.0% at its 12-quarter best), ROCE slipping at 12.1%. The read comes from the last 12 quarters of growth (revenue growth +11.1% latest, profit growth −58.3% latest, eps growth −66.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Camtek Ltd. in an uptrend?
Yes — the price is in a confirmed uptrend (week 1 of stage 2), trading +2.4% versus its 200-day average and at 57% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Camtek Ltd. beating the market?
Not lately — on a trailing-13-week view Camtek Ltd. is currently behind the S&P 500 (7 weeks and counting; last ahead the week of 2026-06-18), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +6,609% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will Camtek Ltd.'s stock price go up?
This page publishes no price forecast for Camtek Ltd. What it measures instead: the stock price is $152, the price is in a confirmed uptrend 1 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Does Camtek Ltd. have too much debt?
It is moderate — Camtek Ltd.'s debt-to-equity is 0.71. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Camtek Ltd.'s capex?
Camtek Ltd. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Camtek Ltd.'s cash flow?
Camtek Ltd. generated $0.1 B of operating cash flow in FY25 and $0.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Camtek Ltd.'s profit real cash?
Yes — over the last 3 fiscal years, 136% of Camtek Ltd.'s reported profit arrived as operating cash. In FY25, operating cash was $0.1 B against reported profit of $0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Camtek Ltd.?
On the balance sheet, the Z-score reads 6.60 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Camtek Ltd. in its business cycle?
Camtek Ltd.'s FY25 operating margin was 26.0%, against a 5-year band of 21.9%–26.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 25.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Camtek Ltd. story?
The sharpest disagreement: the price moved +58.8% in a year while annual EPS moved −57.0% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Camtek Ltd. a stock worth studying right now?
This is not investment advice. The machine read: Camtek Ltd.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.